Published On: Wed, Oct 19th, 2016

Latest Analyst Reports On Infinity Pharmaceuticals, Inc.


Recently stock market analysts have updated their consensus ratings on shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI).

Most recent broker ratings

08/10/2016 – Infinity Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Wedbush. They now have a USD 1 price target on the stock.

06/28/2016 – Infinity Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 2 price target on the stock.

06/15/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at JMP Securities.

06/15/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at Wells Fargo.

06/15/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at William Blair. They now have a USD 2 price target on the stock.

06/15/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “sector perform” by analysts at RBC Capital. They now have a USD 2 price target on the stock.

06/15/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “equal weight” by analysts at Morgan Stanley. They now have a USD 1 price target on the stock.

06/15/2016 – Infinity Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Jefferies.

06/14/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan.

05/14/2015 – Infinity Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Stifel Nicolaus.

05/08/2015 – Infinity Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Nomura. They now have a USD 13 price target on the stock.

05/07/2015 – Deutsche Bank began new coverage on Infinity Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 20 price target on the stock.

04/30/2015 – Infinity Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Zacks.

12/04/2014 – Infinity Pharmaceuticals, Inc. was upgraded to “outperform” by analysts at Credit Suisse. They now have a USD 22 price target on the stock.

09/03/2014 – Infinity Pharmaceuticals, Inc. had its “positive” rating reiterated by analysts at Roth Capital.

Infinity Pharmaceuticals, Inc. has a 50 day moving average of 1.49 and a 200 day moving average of 2.95. The stock’s market capitalization is 67.93M, it has a 52-week low of 1.24 and a 52-week high of 10.85.

The share price of the company (NASDAQ:INFI) was up +2.24%, with a high of 1.40 during the day and the volume of Infinity Pharmaceuticals, Inc. shares traded was 146963.

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.